{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:49:42Z","timestamp":1790171382256,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.eururo.2024.09.005","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T23:44:57Z","timestamp":1726616697000},"page":"579-587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-na\u00efve Prostate Cancer"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1912-042X","authenticated-orcid":false,"given":"Adam B.","family":"Weiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raag","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas K.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Sonni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric V.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaron","family":"Arbet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.H.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Proudfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Hao","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elai","family":"Davicioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanael","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca F.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Dal","family":"Pra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirus","family":"Ghadjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Nickols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jeffrey","family":"Karnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Czernin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashely E.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"Lee Kiang Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.09.005_b0005","first-page":"1288","article-title":"NCCN Guidelines\u00ae insights: prostate cancer, version 1.2023","volume":"20","author":"Schaeffer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2024.09.005_b0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.005_b0015","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","article-title":"Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases","volume":"82","author":"Bostwick","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.09.005_b0020","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euo.2022.04.006","article-title":"Diagnostic performance of prostate-specific membrane antigen positron emission tomography-targeted biopsy for detection of clinically significant prostate cancer: a systematic review and meta-analysis","volume":"5","author":"Kawada","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.09.005_b0025","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer","volume":"76","author":"Paschalis","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.005_b0030","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","article-title":"Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer","volume":"4","author":"Bakht","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.eururo.2024.09.005_b0035","doi-asserted-by":"crossref","first-page":"e162907","DOI":"10.1172\/jci.insight.162907","article-title":"Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer","volume":"8","author":"Sayar","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.eururo.2024.09.005_b0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41586-023-06054-z","article-title":"Pan-cancer whole-genome comparison of primary and metastatic solid tumours","volume":"618","author":"Mart\u00ednez-Jim\u00e9nez","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2024.09.005_b0045","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2024.09.005_b0050","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.eururo.2024.09.005_b0055","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Cancer Genome Atlas Research Network","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2024.09.005_b0060","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.juro.2013.06.017","article-title":"Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population","volume":"190","author":"Karnes","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.09.005_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066855","article-title":"Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy","volume":"8","author":"Erho","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2024.09.005_b0070","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/cncr.34790","article-title":"A novel prostate cancer subtyping classifier based on luminal and basal phenotypes","volume":"129","author":"Weiner","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.09.005_b0075","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1002\/ijc.32430","article-title":"Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma","volume":"145","author":"Alshalalfa","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2024.09.005_b0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","article-title":"Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients","volume":"47","author":"Vaz","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.005_b0085","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2967\/jnumed.118.223099","article-title":"Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade","volume":"60","author":"Emmett","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.005_b0090","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.eururo.2017.03.036","article-title":"Validation of a genomic risk classifier to predict prostate cancer-specific mortality in men with adverse pathologic features","volume":"73","author":"Karnes","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.005_b0095","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.annonc.2021.06.003","article-title":"Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial","volume":"32","author":"Hamid","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.005_b0100","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.005_b0105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bjc.2016.29","article-title":"Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition","volume":"114","author":"Byrne","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2024.09.005_b0110","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1158\/1541-7786.MCR-14-0153-T","article-title":"HIF1\u03b1 regulates mTOR signaling and viability of prostate cancer stem cells","volume":"13","author":"Marhold","year":"2015","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.eururo.2024.09.005_b0115","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1158\/0008-5472.CAN-10-0785","article-title":"Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness","volume":"70","author":"Giannoni","year":"2010","journal-title":"Cancer Research"},{"key":"10.1016\/j.eururo.2024.09.005_b0120","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1089\/ars.2010.3727","article-title":"Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness","volume":"14","author":"Giannoni","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.eururo.2024.09.005_b0125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.celrep.2018.03.086","article-title":"Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images","volume":"23","author":"Saltz","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.eururo.2024.09.005_b0130","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/pros.22980","article-title":"Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells","volume":"75","author":"Diaz","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2024.09.005_b0135","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1470-2045(08)70076-7","article-title":"Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study","volume":"9","author":"Vergis","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.005_b0140","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrc1367","article-title":"Exploiting tumour hypoxia in cancer treatment","volume":"4","author":"Brown","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2024.09.005_b0145","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nature07733","article-title":"Association of reactive oxygen species levels and radioresistance in cancer stem cells","volume":"458","author":"Diehn","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2024.09.005_b0150","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/annonc\/mdx637","article-title":"Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy","volume":"29","author":"Jain","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.005_b0155","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.annonc.2022.05.007","article-title":"Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy \u2013 an ancillary study of the SAKK 09\/10 randomized clinical trial","volume":"33","author":"Dal Pra","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.005_b0160","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3892\/or.2013.2656","article-title":"Screening and identification of significant genes related to tumor metastasis and PSMA in prostate cancer using microarray analysis","volume":"30","author":"Xu","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.eururo.2024.09.005_b0165","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1535-7163.MCT-18-1078","article-title":"A novel fully human antibody targeting extracellular domain of PSMA inhibits tumor growth in prostate cancer","volume":"18","author":"Wu","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eururo.2024.09.005_b0170","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.1038\/s41467-022-33780-1","article-title":"Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease","volume":"13","author":"Wong","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2024.09.005_b0175","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s00259-019-04320-9","article-title":"Diagnostic performance of 68Ga-PSMA PET\/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections","volume":"46","author":"Gao","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.005_b0180","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.eururo.2021.03.017","article-title":"Prostate-specific membrane antigen and fluciclovine transporter genes are associated with variable clinical features and molecular subtypes of primary prostate cancer","volume":"79","author":"Chu","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.005_b0185","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00259-020-04944-2","article-title":"68Ga-PSMA PET\/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer","volume":"48","author":"Roberts","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.005_b0190","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2967\/jnumed.120.254623","article-title":"Intraprostatic tumor segmentation on PSMA PET images in patients with primary prostate cancer with a convolutional neural network","volume":"62","author":"Kostyszyn","year":"2021","journal-title":"J Nucl Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824025971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824025971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T23:47:44Z","timestamp":1733874464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824025971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0302283824025971"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.09.005","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-na\u00efve Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}